About Auspex Pharmaceuticals
Auspex Pharmaceuticals is a company based in Los Angeles (United States) founded in 2001 was acquired by Teva Pharmaceuticals in May 2015. Auspex Pharmaceuticals has raised $90.32 million across 11 funding rounds from investors including Teva Pharmaceuticals, BioMed Realty and Oxford Finance. Auspex Pharmaceuticals operates in a competitive market with competitors including Biogen, Denali Therapeutics, Annexon, Entrada Therapeutics and Adamas Pharma, among others.
- Headquarter Los Angeles, United States
- Stage Public
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website auspexpharma.com
- Social LinkedIn
- Acquired by Teva Pharmaceuticals (May 2015)
- Legal Name Auspex Pharmaceuticals, Inc.
- Net Profit-$59.54 M (USD)-281as on Dec 31, 2014
- EBITDA-$50.26 M (USD)-281as on Dec 31, 2014
- Total Equity Funding$90.32M (USD)
in 11 rounds
- Latest Funding Round$20M (USD), Series E
Jan 2014
- InvestorsTeva Pharmaceuticals
& 5 more
- Acquired byTeva Pharmaceuticals
(May 2015)
Funding Insights of Auspex Pharmaceuticals
Auspex Pharmaceuticals has successfully raised a total of $90.32M across 11 strategic funding rounds. The most recent funding activity was a Series E round of $20 million completed in January 2014. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $90.32M
- Total Rounds 11
- Last Round Series E — $20M
- First Round $5M
(Feb 2009)
- Investors Count 5
Latest 10 of 11 funding rounds of Auspex Pharmaceuticals with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan 2014 | $15M | Debt – Venture | – | – | |
| Jan 2014 | $20M | Series E | – | – | |
| Sep 2013 | $27.99M | Series D | – | Panorama Capital, Thomas, McNerney & Partners | – |
| Jul 2012 | $1.5M | Series D | – | – | – |
| Dec 2011 | $3M | Series D | – | – | – |
| Jul 2010 | $13.83M | Series C | – | – | – |
| Jul 2010 | $12M | Series C | – | – | – |
| Jan 2010 | $2M | Series C | – | – | – |
| Oct 2009 | $2M | Series C | – | – | – |
| Aug 2009 | $3M | Series C | – | – | – |
6 investors in total: 6 institutional.
Investors in Auspex Pharmaceuticals
Auspex Pharmaceuticals has secured backing from 6 investors, including venture fund and institutional investors. Prominent investors backing the company include Teva Pharmaceuticals, BioMed Realty and Oxford Finance.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture debt firm focused on the life sciences sector | 2002 | oxfordfinance.com | Alexandria, United States | |
- | – | tm-partners.com | - | |
Early & later stage venture capital firm investing in the US | – | panoramacapital.com | Campbell, United States | |
Healthcare ecosystem is supported through investment and innovation by Deerfield. | – | deerfield.com | New York, United States | |
REIT focused on providing properties to life science communities. | 2004 | biomedrealty.com | San Diego, United States | |
Generic pharmaceuticals are manufactured by Teva Pharmaceuticals. | 1901 | tevapharm.com | Petah Tikva, Israel |
Investor details for Auspex Pharmaceuticals
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Auspex Pharmaceuticals
5 dated milestones of Auspex Pharmaceuticals across 14 years, from founding to its latest funding, stage changes and deals.
- Founded Auspex Pharmaceuticals is founded.
- Funding First funding round of $5.0M.
- Funding Latest funding round, Series E, of $20.0M.
- IPO Lists on the stock exchange (IPO).
- Exit Acquired by Teva Pharmaceuticals.
Competitors of Auspex Pharmaceuticals
Auspex Pharmaceuticals operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Biogen, Denali Therapeutics, Annexon, Entrada Therapeutics and Adamas Pharma, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| biogen.com | 1978 | Cambridge, United States | $80M | 1 | Therapies for neurodegenerative and immunology disorders are developed. | |
| denalitherapeutics.com | 2015 | San Francisco, United States | $347M | 377 | Neurodegenerative disease therapies are developed for Alzheimer's, ALS, and Parkinson's. | |
| annexonbio.com | 2011 | San Francisco, United States | $256M | 80 | Developer of antibodies to treat complement-mediated neurodegenerative diseases | |
| entradatx.com | 2016 | Boston, United States | $175.25M | 122 | Biologics platform developed for intracellular delivery in rare diseases. | |
| adamaspharma.com | 2002 | Emeryville, United States | $68.03M | 142 | Pharmacokinetic profiles of approved drugs are enhanced for CNS therapeutics. | |
| sonomabio.com | 2012 | San Francisco, United States | $335M | 74 | T-cell-based therapies for autoimmune and degenerative diseases are developed. | |
| intracellulartherapies.com | 2002 | New York, United States | $80.87M | 600 | Developer of therapeutics for psychiatric and neurologic diseases | |
| juvlabs.com | 2017 | Dublin, Ireland | $289.89M | – | Provider of proprietary ketone ester-based therapeutic drink for age-related disorders and metabolic health | |
| alector.com | 2013 | San Francisco, United States | $214.78M | 211 | Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | |
| bluerocktx.com | 2016 | Boston, United States | $225M | 138 | Stem cell therapies are developed for cardiovascular and neurological diseases. |
Detailed competitors of Auspex Pharmaceuticals
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Auspex Pharmaceuticals
Websites that share an audience with Auspex Pharmaceuticals (auspexpharma.com).
Websites whose visitors overlap most with Auspex Pharmaceuticals. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| vicortech.com | 100% | – | – | View details | |
| prosidion.com | 100% | – | – | View details | |
chemovation.com | chemovation.com | 100% | – | – | – |
phytopharm.com | phytopharm.com | 100% | – | – | – |
| biotrondiagnostics.com | 100% | 1.5K | #9,362,675 | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 21 similar websites and full traffic analytics for Auspex Pharmaceuticals
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 21 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Latest news on Auspex Pharmaceuticals
Complete news archive for Auspex Pharmaceuticals
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to Auspex Pharmaceuticals
10 companies that operate in the same segment as Auspex Pharmaceuticals (Neurology), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Novel biopharmaceutical medicines are developed for unmet medical needs. | 2003 | Dublin, Ireland | USD 265 M | USD 4.27 B | 2,800 | |
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 | |
Developer of therapeutics for psychiatric and neurologic diseases | 2002 | New York, New York, United States | USD 80.87 M | USD 250.31 M | 600 | |
Biologics platform developed for intracellular delivery in rare diseases. | 2016 | Boston, Massachusetts, United States | USD 175.25 M | USD 25.42 M | 183 | |
Developer of therapies for the treatment of musculoskeletal disorders | 2007 | Woburn, Massachusetts, United States | USD 62 M | USD 85.55 M | 692 | |
MR-interfaced ultrasound devices for cancer and neurology treatments are provided. | 1999 | Tirat Carmel, Haifa District, Israel | USD 574.2 M | – | – | |
AI-driven drug discovery platform for neurological diseases based on patients biomarkers | 2019 | San Francisco, California, United States | USD 144.72 M | – | 76 | |
Small molecule drugs for rare diseases are developed. | 1998 | South Plainfield, New Jersey, United States | USD 248.1 M | USD 1.73 B | 939 | |
Developer of small molecule therapeutics for endocrine and CNS disorders | 1992 | San Diego, California, United States | USD 10 M | USD 2.86 B | 1,800 | |
Developer of antibodies to treat complement-mediated neurodegenerative diseases | 2011 | San Francisco, California, United States | USD 256 M | – | 100 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Auspex Pharmaceuticals
Auspex Pharmaceuticals was founded in 2001 and raised its 1st funding round 8 years after it was founded.
Auspex Pharmaceuticals is headquartered in Los Angeles, United States. It is registered at Los Angeles, California, United States.
Auspex Pharmaceuticals is a funded company, having raised a total of $90.32M across 11 funding rounds to date. The company's 1st funding round was a Series C of $3M, raised on Feb 2009.
Auspex Pharmaceuticals is a US-based, NDA-ready biopharma developing small molecule therapeutics for neurodegenerative diseases. The company was acquired by Teva in 2015 for USD 3.2Bn. The companys lead candidate is SD-809 (small molecule inhibitor) which completed Phase 3 trial for chorea associated with Huntingtons disease, in 2010. SD-809, or Deutetrabenazine, is a small molecule inhibitor of the Vesicular Monoamine-2 Transporter, or VMAT2, which regulates the levels of dopamine in the brain. SD-809 is also undergoing trial as potential treatment for tardive dyskinesia. Other compounds SD-560 and SD-809 (tics associated with tourette syndrome) are in clinical phase trial 1 and 1b.
Auspex Pharmaceuticals's top competitors include Alector, Intra-Cellular Therapies and Entrada Therapeutics.
Auspex Pharmaceuticals has 6 investors. Key investors include Teva Pharmaceuticals, BioMed Realty, Oxford Finance, Thomas, McNerney & Partners, and Panorama Capital.
Auspex Pharmaceuticals operates through Auspex Pharmaceuticals, Inc..
Yes. Auspex Pharmaceuticals was acquired by Teva Pharmaceuticals in May 2015.